To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes.

What this study involves

The registry says this study is recruiting. Individual locations may have different availability.

Study type

Interventional

Phase

Not applicable

Age range

18 years - Not specified

Sex eligible

All sexes

Healthy volunteers

Not accepted

Participants

34 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

The goal of this clinical trial is to evaluate the efficacy and safety of Medtronic 780G automated insulin delivery system in adult persons with type 1 diabetes and gastroparesis.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion criteria

• Age ≥18 years
• Diagnosis of T1D for at least 12 months with stable insulin regimen for at least 2 months
• HbA1c ≥8.0%
• Diagnosis of gastroparesis per National Institute of Health (NIH) definition
• Willing to use Medtronic 780G system either with Simplera CGM.
• Ability to provide informed consent before any trial-related activities
• If randomized to usual care group and on an insulin pump already, should be willing to use pump in manual mode only for the duration of the study

Exclusion criteria

• Age \<18 years
• Current use of inhaled insulin (Afrezza)
• Patients with T1D using any glucose lowering medications other than insulin at the time of screening
• Pregnancy, breast feeding, or wanting to become pregnant
• Current use (≥ 2 weeks of continuous use) of any steroidal medication, or anticipated long-term steroidal treatment (\>4 weeks continuously), during the study period
• History of gastric outlet obstruction or other gastrointestinal structural abnormalities
• Estimated glomerular filtration rate (eGFR) \<30 or on dialysis
• History of SH in the previous 3 months
• History of two or more episodes DKA requiring hospitalization in the past 12 months
• Any medical (such as severe cardiovascular disease, malignancy, chronic liver disease) or psychosocial conditions that make a person unfit for the study at the discretion of investigators
• Use of investigational drugs within 5 half-lives prior to screening
• Current use of cannabis or history of cannabinoid hyperemesis syndrome

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Random assignment

Masking

No masking

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Secondary measures

Other measures

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Study team and timeline

Lead sponsor

Viral N. Shah

Study start

Feb 9, 2026 Actual

Primary completion

Apr 1, 2027 Estimated

Study completion

Apr 1, 2027 Estimated

First posted

Dec 17, 2025 Actual

Last updated

Nov 10, 2026 Actual

Official study contacts